Results 181 to 190 of about 15,932 (195)

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2010
Clifford J Bailey, James F List
exaly  

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, 2019
Claire C J Dekkers, C David Sjöström, Peter J Greasley   +2 more
exaly  

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

Diabetes Care, 2018
Fredrik Thoren, John Xu, Roger Chen
exaly  

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

Diabetes, Obesity and Metabolism, 2018
Serge A Jabbour, Jochen Seufert, André J Scheen   +2 more
exaly  

Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes

Diabetes, Obesity and Metabolism, 2013
Hiddo J L Heerspink, Dick De Zeeuw
exaly  

Dapagliflozin

2013
openaire   +1 more source

Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

Diabetes, Obesity and Metabolism, 2011
Marc Pfister, D W Boulton
exaly  

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Diabetes Care, 2018
Chantal Mathieu, Christoph Hasslacher, Eiichi Araki   +2 more
exaly  

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice

Diabetes, Obesity and Metabolism, 2014
D G Parkes
exaly  

Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

Lancet, The, 2023
exaly